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ABSTRACT: Large bone defects are ideally treated with autografts, which have many limitations. Therefore, osteoconductive scaffolds
loaded with autologous bone marrow (BM) aspirate are increasingly used as alternatives. The purpose of this study was to compare the
growth of multipotential stromal cells (MSCs) from unprocessed BM on a collagen-containing bovine bone scaffold (Orthoss1 Collagen)
with a non-collagen-containing bovine bone scaffold, Orthoss1. Another collagen-containing synthetic scaffold, Vitoss1 was included in
the comparison. Colonization of scaffolds by BM MSCs (n¼23 donors) was evaluated using microscopy, colony forming unit-fibroblast
assay and flow-cytometry. The number of BM MSCs initially attached to Orthoss1 Collagen and Vitoss1 was similar but greater than
Orthoss1 (p¼ 0.001 and p¼ 0.041, respectively). Furthermore, the number of MSCs released from Orthoss1 Collagen and Vitoss1 after
2-week culture was also higher compared to Orthoss1 (p¼0.010 and p¼ 0.023, respectively). Interestingly, collagen-containing scaffolds
accommodated larger numbers of lymphocytic and myelomonocytic cells. Additionally, the proliferation of culture-expanded MSCs on
Orthoss1 collagen and Vitoss1 was greater compared to Orthoss1 (p¼ 0.047 and p¼0.004, respectively). Collectively, collagen-containing
scaffolds were superior in supporting the attachment and proliferation of MSCs when they were loaded with unprocessed BM aspirates.
This highlights the benefit of collagen incorporation into bone scaffolds for use with autologous bone marrow aspirates as autograft
substitutes.  2015 The Authors. Journal of Orthopaedic Research Published by Wiley Periodicals, Inc. on behalf of Orthopaedic Research
Society. J Orthop Res 34:597–606, 2016.
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Non-union or delayed bone healing is still a problem in
a considerable number of injuries associated with
fractures and/or bone loss.1 The gold standard therapy
for fracture non-union remains the implantation of
bone autograft.2 However, its use is associated with
problems including limited accessibility, formation of
haematoma, bleeding, infection, and harvest-related
pain.3,4 The use of autograft substitutes, such as
allograft scaffolds provides a valid alternative, particu-
larly when these scaffolds are loaded with autologous
bone marrow (BM) aspirates, growth factors or their
combination.5,6 Autologous BM aspirates contain oste-
ogenic progenitors, multipotential stromal cells
(MSCs), which are crucial players in the process of
bone repair.7,8 MSC-loaded scaffolds have shown effec-
tiveness in the experimental animal models of bone
defects 9–11 and consequently have become a promising
therapeutic method in the discipline of orthopaedic
surgery.11,12
To enhance the repair of complicated bone frac-
tures, there are many types of osteoconductive scaf-
folds composed of either natural hydroxyapatite or
synthetic materials, available for clinical use. The
synthetic scaffolds are formed of inorganic calcium
phosphate, polymers or composites of these materi-
als.5,13 Extracellular matrix (ECM) is formed of
various proteins including collagen types I and II,
fibronectin, biglycan, decorin, perlecan, and laminin.
These components form the niche for BM MSCs in
vivo and provide the mechanical and biological support
for MSCs in order to respond to the surrounding
signals favoring bone formation.14 As a major compo-
nent of ECM, collagen is used as a natural biocompati-
ble polymer for bone substitution but it has poor
mechanical properties. Thus, collagen is usually com-
bined with other bone substitute materials.5,15
Studies analysing the biology of MSCs loaded on
scaffolds particularly collagen-containing ones have
been most commonly performed using culture-expand-
ed MSCs.16,17 Bone scaffolds are commonly soaked in
unprocessed BM aspirates intra-operatively prior to
use for treatment of non-union. However, little is
known about how efficient is BM MSC attachment to
scaffolds and how the modification of scaffold composi-
tion, such as collagen incorporation could affect coloni-
zation of these scaffolds by MSCs.
The aim of this study was to investigate the impact
of collagen addition to a bovine bone allograft scaffold,
on the attachment and proliferation of non-cultured
MSCs, i.e., derived from unprocessed BM aspirates. A
bovine bone scaffold, Orthoss1 (non-collagen contain-
ing) was used as a control for the collagen-containing
one, Orthoss1 collagen. Another collagen-containing
synthetic bone scaffold, Vitoss1, was also included in
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the study. Using unprocessed BM aspirates, we aimed
to quantify rare MSCs, which were able to attach,
survive and proliferate on these scaffolds.
MATERIALS AND METHODS
Scaffolds
The scaffolds used in this study were: Orthoss1, Orthoss1
Collagen (Geistlich Surgery, Wolhusen, Switzerland) and
Vitoss1 (Stryker, Malvern, PA). Orthoss1 is a bovine bone
mineral, i.e., hydroxyapatite with nano pores (10–20nm)
and macro pores (100–300mm). Orthoss1 Collagen is a
similar material as Orthoss1 but is complemented with 10%
porcine collagen. Vitoss1 is a synthetic beta-tricalcium
phosphate with pores of variable size (1–1,000mm) and is
supplemented with type I bovine collagen. Orthoss1 was
provided as 2–4mm granules of total 7 g and with an average
volume of 8mm3 per granule. The whole Orthoss1 Collagen
scaffold block (500mg, 10 10 8mm, 0.8 cc), was divided
into eight equal pieces each of 100mm3 volume. Vitoss1
strip (25 100 4mm, 10 cc) was punched using 4mm sterile
disposable biopsy punch with plunger (Miltex, NJ) into
50mm3 particles. To standardize the volume of all scaffolds
(100mm3); 12 granules of Orthoss, one piece of Orthoss1
Collagen and two particles of Vitoss1 were used for each
experiment.
Patients and Bone Marrow Samples
Following ethic committee approval (06/Q1206/127, National
Research Ethics Committee Yorkshire & Humber–Leeds
East), BM aspirates were obtained from the iliac crest of
twenty three consented patients; 13 males and 10 females
with median age of 47 years, range 14–82. All patients were
undertaking elective orthopaedic surgery for various rea-
sons but reported as having no underlying diseases. Ten
millilitre of BM was aspirated using bevel tipped trocar
needle (Stryker 306–111, 11-gauge, MI) and a single
draw method and then placed in two EDTA containing
VACUETTE1 blood collection tubes. In some experiments,
culture-expanded MSCs from seven donors were used.
Culture-expanded MSCs were generated as previously de-
scribed18 and grown in Stem MACS MSC Expansion media
(Miltenyi Biotec, Surrey, UK) supplemented with penicillin/
streptomycin (Sigma–Aldrich, St. Louis) at 37˚C/5% CO2
culture condition.
Loading Scaffolds With Bone Marrow Aspirates or Culture-
Expanded MSCs
BM aspirates were thoroughly mixed then 500ml of the
aspirate was incubated with 100mm3 of each of
three scaffolds. The same BM sample was used to load the
three scaffolds in each experiment. Several replicates were
performed depending on the type of experiment. The scaf-
folds were incubated with BM aspirate for one and half or
three hours at 37˚C with gentle rotational movement using a
rotator with reciprocal turning angle, 45˚ and vibration
angle, 5˚ (Biosan, Riga, Latvia), as described previously.19 In
some experiments, scaffolds were similarly incubated with
passage three culture-expanded MSCs (average of 2 105
MSCs in 500ml of media/100mm3 of each scaffold). Following
incubation, scaffolds were gently rinsed in phosphate-buff-
ered saline (PBS, Invitrogen, Paisley, UK) and then cultured
in Stem MACS media. The culture media was half changed
every 2–3 days to take the advantage of MSC autocrine
activation of their proliferation.20
Colony Forming Unit-Fibroblast Assay
The number of MSCs initially attached to scaffolds was
detected using Colony Forming Unit-Fibroblast (CFU-F)
assay to enumerate of the number of MSCs in BM aspirates
before and after loading on scaffolds. To assess MSC
numbers in BM aspirate before loading on scaffolds (pre-
loading control), 200ml of BM aspirate was added to 15ml of
Stem MACS media and then seeded in duplicate in 10 cm
diameter culture dishes (Corning Life Sciences, Amsterdam,
Holland). The media were replaced 48h later to remove non-
adherent cells and the culture was continued for 14 days.18
The resulting colonies were counted after staining with
methylene blue. The assay was repeated on the BM aspirates
left at the end of incubation with the scaffolds (post-loading
control). The numbers of MSCs attached to scaffolds were
calculated using pre and post loading controls. As scaffolds
are known to be different in their porosity and hence the
amount of liquid that can be absorbed inside,21 the volume of
non-bound BM sample was recorded and used in the subse-
quent calculations of attached MSCs.
Environmental Scanning Electron Microscopy
Scaffolds loaded with BM aspirates were processed for
Environmental Scanning Electron Microscopy (ESEM) to
examine cell attachment on the surface of scaffolds after
2-week cultivation, as previously described.19 Briefly, scaf-
folds were removed from the culture, washed twice with
PBS and then fixed in 10% formalin. Empty scaffolds were
similarly cultured and processed as negative controls.
ESEM was performed using S-3700N scanning electron
microscope (Hitachi, Berkshire, UK). Images were captured
of hydrated samples under low vacuum and variable
pressure at 20˚C.
Histology
Histology was used to assess the presence of attached MSCs
on the surface and inside scaffolds after 2-weeks of culture.
After harvesting from culture, scaffolds were gently washed
with PBS and subsequently, kept in 10% formalin for cell
fixation for at least 24h before being processed for histology.
Empty scaffolds were included as negative controls. Speci-
mens were embedded in paraffin and subsequently, cut into
5mm sections using a Leica RM2255 microtome. Orthoss
required decalcification to facilitate the sectioning of the
scaffold, using EDTA solution (250 g disodium EDTA and
1750ml deionised water, pH 7.0) for 2–3 days. The slides
were processed for a routine staining with haematoxylin and
eosin (H&E), and scanned under bright-field mode using
Nikon microscope E1000. Nuance V.3.0.1.2 software (Perkin
Elmer) was used to acquire the images.
Digestion of Scaffolds and Release of Cells
To release the cells from the scaffolds following the culture,
the scaffolds were gently washed with PBS and subsequently,
treated with 1% trypsin (Sigma–Aldrich) for 10min at 37˚C.
More tightly attached cells were subsequently released using
0.25% collagenase (Stem Cell Technologies, Grenoble,
France). For each scaffold, 0.5ml collagenase was added for
30min and incubated at 37˚C with slight agitation using
VIBRAX-VXR shaker (IKA, Staufen, Germany). The digested
fraction was next passed through 70mm cell strainer (BD
falcon) to separate cells from the scaffold debris. Cells were
then washed in PBS and re-suspended in 50ml of blocking
buffer (10% of mouse serum and human IgG1, Sigma–Aldrich)
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to prevent nonspecific binding before being processed for flow-
cytometry staining.
Surface Phenotype and Quantification of MSCs Released From
Scaffolds
Flow-cytometry was performed to assess the standard pheno-
type of culture-expanded MSCs.22,23 The antibodies against
CD90 (Bio-Rad, Hertfordshire, UK), CD45, CD73, CD105,
CD13, CD106, CD146, and CD166 (all from BD Biosciences)
were used. To identify MSCs released after digestion of
scaffolds, the antibodies against CD90, CD73, and CD45 were
used. All antibodies were applied at the manufacturer’s recom-
mended concentrations and the staining was performed for
30min at room temperature in the dark. Live/Dead1 Violet
Viability Kit (Molecular Probes, Life Technologies, Paisley, UK)
was used to exclude debris from data analysis and to evaluate
the proportions of live and dead cells. The total number of MSCs
released from each scaffold was calculated using CountBrightTM
absolute counting beads (Molecular probes, Invitrogen, UK)
using the manufacture’s recommended formula: Cell count per
ml¼ (number of live cell events/number of beads events) 
(assigned bead count of the bead lot/Volume of sample). The
data were acquired on LSRII (BD Biosciences) and analysed
using BD FACS DivaTM software (BD Biosciences).
Proliferation of Culture-Expanded MSCs
To assess the proliferation of culture-expanded MSCs loaded
on the bone scaffolds, these MSCs were first serum starved
for 12h in 1 g/l glucose containing DMEM medium to
synchronize their cell cycle status before incubation with
scaffolds.24 On the day of experiment, MSCs were trypsinised
and then labeled with 1mM of Carboxyfluorescein succini-
midyl ester (CFSE) (Cell TraceTM CFSE Cell Proliferation
Kit, Life technologies, Paisley, UK). Cells were then washed,
re-suspended in Stem MACS media and incubated with each
of three scaffolds for 3 h before being transferred to the
culture. A part of MSCs not incubated with scaffolds was
processed for flow-cytometry to determine “day 0” expression
level of CFSE. After 4 days, the scaffolds were digested and
MSCs were released and then stained for flow-cytometry to
determine their CFSE levels. Overlapping histogram panels
for CFSE staining were performed using Kalusa 1.3 analysis
software (Beckman coulter).
Statistical Analysis
The graphs were prepared using the GraphPad Prism 6. All
statistics were performed using IBM SPSS1 21 statistics
software. The comparison of the numbers and percentages of
attached or proliferated MSCs, and other cells between the
three scaffolds were analyzed using Friedman’s Two-way
Analysis of Variance (ANOVA) test. Then, the pairwise compar-
isons were performed using Dunn–Bonferroni tests. To compare
the number of aspirated BM MSCs between male/female or
between younger/older donors, unpaired t-test was applied. The
correlation was performed using Spearman’s rho test.
RESULTS
Attachment of Non-Cultured BM MSCs to Scaffolds
The total number of non-cultured MSCs attached to
scaffolds was calculated by counting colony-forming
MSCs before and after 3h incubation between unpro-
cessed BM and scaffolds (Fig. 1).
Experiments performed on 10 independent BM
aspirates revealed that the total number of BM MSCs
attached to Orthoss1 collagen and Vitoss1, was
not significantly different (median values of 126 and
117 MSCs/100mm3 of scaffold, respectively, p¼0.791)
(Fig. 1A). However, the number of BM MSCs attached
to Orthoss1 collagen and Vitoss1 was significantly
higher (two fold, p¼0.001 and p¼0.041, respectively)
compared to Orthoss1 (median 60 MSCs/100mm3 of
scaffold, Fig. 1A). This indicated that the collagen-
containing scaffolds were superior compared to
Orthoss1 in supporting the attachment of rare MSCs
from unprocessed BM aspirates.
The number of attached MSCs was widely variable
between donors (Fig. 1A) and significantly correlated
with the initial counts of MSCs in BM aspirates
independently of the scaffold type (Orthoss1 collagen:
p¼ 0.001, Orthoss1: p¼0.003 and Vitoss1: p<0.001)
(Fig. 1B). There was no statistical significant differ-
ence in the frequencies of aspirated MSCs between
male and female donors (mean values 405 and 315
MSCs/ml of BM), whereas BM aspirates from older
donors (>45 years old) had fewer MSCs compared to
younger donors (45 years old) (mean values 163 and
532 MSCs/ml of BM, respectively, p¼ 0.0145).
When MSC attachment data were reanalyzed
according to the age and gender of donors, no preferen-
tial attachment of a certain group (male/female or
young/old) was found. The numbers of attached BM
MSCs from both male and female donors were similarly
distributed on the scaffolds (Fig. 1A). In summary,
scaffolds with high numbers of attached MSCs corre-
sponded to BM aspirates from a “younger” group of
donors, reflecting their higher initial frequencies in
these donors.
The study of incubation times shorter than 3h was
clearly merited, considering scaffolds are loaded with
BM aspirates in operating theatres. Using a subset of
samples (n¼4), we next investigated if shortening the
incubation time by half could impair MSC attachment.
Interestingly, no decrease was found in the number of
MSCs attached to the three scaffolds following 1.5h
long incubation, compared to 3h (Fig. 1C).
Overall, these data revealed that, despite the infre-
quency and variable numbers of MSCs in BM aspirates,
these rare MSCs were able to attach to the tested
scaffolds. Interestingly, the collagen-containing scaf-
folds (Orthoss1 collagen and Vitoss1) have provided
better support for the initial MSC attachment compared
to the non-collagen-containing scaffold, Orthoss1.
Microscopic Visualization of MSC Attachment to Scaffolds
We next aimed to examine the surface of these
scaffolds and to visualize cells, which attached and
survived on the three scaffolds after 2-weeks of culture
using ESEM and histology (Figs. 2 and 3). Using
ESEM on empty scaffolds revealed their basic surface
architecture. The surface of both of Vitoss1 and
Orthoss1 collagen was mostly covered by collagen
fibers with visible parts of bone mineral, in contrast to
Orthoss1, which had a smooth surface of pure bone
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Figure 2. The surface topography and MSC attachment on scaffolds using ESEM; Empty (top panels) or BM aspirate-loaded scaffolds
(bottom panel) were examined after 2-week culture. Scale bar¼50mm.
Figure 1. Attachment of unprocessed BM MSCs to Orthoss
1
collagen, Orthoss
1
, and Vitoss
1
; (A) The number of MSCs attached to
the three scaffolds (3h incubation, n¼ 10 donors, p¼0.001, #p¼0.041). The numbers were calculated from MSC counts before and
after loading of scaffolds with BM aspirate using CFU-F assay. OC: Orthoss
1
collagen, O: Orthoss
1
, and V: Vitoss
1
. M: male, F: female,
O: old, Y: young. (B) The correlation between the numbers of seeded MSCs and the number of MSCs attached to the three scaffolds.
Orthoss
1
collagen: r¼0.87, p¼0.001, Orthoss1: r¼0.83, p¼0.003, Vitoss1: r¼0.93, p< 0.001. (C) The number of MSCs attached to
three scaffolds after 1.5 h compared to 3h incubation (n¼4 donors).
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mineral (Fig. 2, top panels). For this reason, cells
attached to the surface of Orthoss1 were clearly
visible as flat and branched cells bridging scaffold
pores (Fig. 2, bottom middle panel). It was hard to
detect similar cells on the surface of Vitoss1 or
Orthoss1 collagen due to their surface coverage with
collagen (Fig. 2, bottom left and right panels). Howev-
er, the smoothness of collagen fibres and increased
coverage of mineral parts on the surface of these
scaffolds when compared to controls suggested a
presence of attached cells.
The inner structure of scaffolds was examined using
H&E-stained sections of the empty scaffolds (Fig. 3, left
panel). The scaffolds seeded with culture-expanded
MSCs and used as positive controls, showed a presence
of elongated or rounded cells mostly attached to or near
the surface of the three scaffolds (Fig. 3, right panel).
Cells resembling culture-expanded MSCs were also
detected on the surface and inside the scaffolds loaded
with BM aspirate (Fig. 3, middle panel, A). Additionally,
smaller round cells were also found inside scaffolds
loaded with BM aspirates (Fig. 3, middle panel, B).
This indicated that a variety of BM-derived cells could
attach and survive inside these scaffolds.
Quantification of BM MSCs Released From Scaffolds
Following In Vitro Culture
Cells released from scaffolds were next analyzed by
flow-cytometry in order to confirm the presence of
MSCs, and detect which of the three examined scaf-
folds best supported the survival of MSCs (Fig. 4).
Live cells were identified based on positive staining
with live cell marker, Calcein violet and negative
staining with Aqua dye, which only stains dead cells.25
The percentages of dead cells (Aqua positive cells after
exclusion of debris) in relation to total released cells
were similar in all three scaffolds (mean: 29%, 33%,
and 30% for Orthoss1 collagen, Orthoss1 and Vitoss1,
respectively). Based on cell scattering characteristics
and CD45 expression, the lymphocytic lineage cells
were detected as CD45brightSSClow and myelomono-
cytic lineage cells as CD45medSSCmed (Fig. 4A).26
Within the CD45-negative fraction, MSCs were identi-
fied as CD73þCD90þ cells (Fig. 4A).
After 2-weeks of culture, the numbers of live MSCs
released from Orthoss1 collagen and Vitoss1 were
significantly higher (nearly threefold and twofold
respectively, p¼ 0.010 and p¼ 0.023, respectively)
compared to Orthoss1 (Fig. 4B, left panel). In con-
trast, the difference between the number of live MSCs
released from Orthoss1 collagen and Vitoss was mini-
mal (Fig. 4B, left panel). This indicated that the
collagen-containing scaffolds provided a greater sup-
port for the survival of BM MSCs. However, the
percentages of MSCs in relation to total live cells
released from Orthoss1 were significantly higher
compared to Orthoss1 collagen (threefold, p¼0.032)
and Vitoss1 (3.5-fold, p¼0.024) (Fig. 4B, right panel).
The number of lymphocytic and myelomonocytic
cells released from Orthoss1 collagen and Vitoss1
was higher than those released from Orthoss1 (nearly
10-fold & 11-fold, p¼0.045 and p¼0.004 for both
lymphocytic and myelomonocytic cells, respectively)
(Fig. 4C). However, there was no significant differ-
ence between the number of these cells released
from Orthoss1 collagen and Vitoss1. Additionally,
Figure 3. Histological assessment of MSC attachment to scaffolds using H&E staining; Empty (left panels), BM aspirate-loaded
(middle panels, A and B) and culture-expanded MSC-loaded (right panels) scaffolds after 2-week culture. Black arrows indicate
putative MSCs and yellow arrows indicate other BM cells. Scale bar¼20mm.
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Figure 4. Quantification of MSCs and other BM cells released from BM-loaded scaffolds; (A) Gating strategy using flow-cytometry:
Lymphocytic cells (L) as CD45brightSSClow, Myelomonocytic cells (M) as CD45medSSCmed and MSCs as CD45-CD73þCD90þ cells. (B)
Total numbers of MSCs released from the scaffolds following 2-week culture (left panel, n¼ 7 donors) p¼ 0.010, #p¼ 0.023. Counting
beads were used for absolute quantification. The percentage of MSCs out of total live cells released from the scaffolds following 2-week
culture (right panel, n¼ 12 donors). p¼0.032, #p¼0.024. OC: Orthoss1 collagen, O: Orthoss1, and V: Vitoss1. (C) Total numbers of
lymphocytic cells (left panel) and myelomonocytic cells (right panel) released from the scaffolds following 2-week culture (n¼ 7 donors).
For both; panels p¼0.045, #p¼ 0.004. (D) The correlation between the number of MSCs and the number of lymphocytic (L) and
myelomonocytic cells (M) released from the three scaffolds following 2-week culture. Orthoss1 collagen: R¼ 0.99, p< 0.001 and
r¼ 0.85, p¼ 0.014. Orthoss: R¼ 0.82, p¼ 0.023 and r¼ 0.89, p¼ 0.007. Vitoss: R¼0.85, p¼0.014 and r¼0.8, p¼ 0.036 for MSCs
versus myelomonocytic and lymphocytic cells, respectively. (E) Fold increase in MSC numbers released from scaffolds cultured for 2
and 5 weeks relative to MSC number counted after 1-week culture. Samples from three different BM donors are shown.
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we observed significant positive correlations between
the number of released MSCs and lymphocytic or
myelomonocytic cells, respectively (Orthoss1 colla-
gen: p<0.001 and p¼0.014, Orthoss1: p¼ 0.023 and
p¼0.007 and Vitoss1: p¼0.014 and p¼0.036)
(Fig. 4D). These data demonstrated that the collagen-
containing scaffolds played a positive role in support-
ing the survival of MSCs as well as different types of
BM cells.
Comparing Figures 1 and 4, it was clear that the
numbers of BM MSCs attached to the scaffolds were
lower than the numbers of BM MSCs released from
scaffolds after 2-weeks of culture. This indicated
that BM MSCs were proliferating inside these scaf-
folds. To compare how effectively the scaffolds
supported the proliferation of MSCs, three different
BM aspirates were used to load scaffolds and
subsequently, cultured for 1, 2, and 5 weeks in a
time-course fashion (Fig. 4E). We then compared the
numbers of MSCs released from the scaffolds after 2
and 5 weeks of culture relative to the numbers
measured after 1-week of culture. The data demon-
strated that the increase of MSC counts either after
2 or 5 weeks culture on Vitoss1 or Orthoss1
collagen was greater compared to that on Orthoss1
(Fig. 4E). These data indicated that all three
scaffolds supported the proliferation of attached BM
MSCs, but collagen-containing scaffolds outper-
formed Orthoss1 within that respect.
The Proliferation of Culture-Expanded MSCs
Inside Scaffolds
To confirm that collagen-containing scaffolds support
the proliferation of MSCs better than Orthoss1, we
seeded the three scaffolds with a pure population
of culture-expanded MSCs. Before seeding on scaf-
folds, culture-expanded MSCs were characterized by
flow-cytometry using the standard MSC markers.22,23
All culture-expanded MSCs used in these experiments
were >90% positive for CD73, CD90, CD105, CD166,
CD146, and CD13, 80% positive for CD106, and were
negative for CD45 (Fig. 5A).
Figure 5. The proliferation of culture-expanded MSCs inside scaffolds; (A) The surface phenotype of culture-expanded MSCs before
being seeded on scaffolds (n¼4 donors). Error bars indicate standard deviation. (B) The percentages of CD90þ CD73þ MSCs released
from scaffolds following 2-week culture compared to plastic adherent MSCs. OC: Orthoss
1
collagen, O: Orthoss
1
, V: Vitoss
1
, and PA:
plastic adherent. (C) Total numbers of culture-expanded MSCs after 4 days of culture on scaffolds (n¼7 donors). p¼ 0.046, #p¼0.004.
(D) Left panel: CFSE-staining levels of culture-expanded MSCs released from a scaffold on day 5 (grey histogram) compared to its
levels before seeding (day 0, black histogram). Right panel: The total numbers of MSCs that proliferated during 4 days of in vitro
culture on scaffolds (n¼ 7 donors) p¼ 0. 047, #p¼ 0.004.
MSC GROWTH ON COLLAGEN-CONTAINING SCAFFOLDS 603
JOURNAL OF ORTHOPAEDIC RESEARCH APRIL 2016
Culture-expanded MSCs seeded on scaffolds were
released and characterized using Live/Dead cell
markers, CD45, CD73, and CD90. As expected, MSC
population was predominant (Fig. 5B). Consistent with
data obtained with BM aspirates, the total number of
culture-expanded MSCs released from Orthoss1 colla-
gen and Vitoss1 was significantly higher compared to
those extracted from Orthoss1 (p¼ 0.046 and p¼0.004,
respectively) (Fig. 5C) confirming that collagen-contain-
ing scaffolds support better the survival of MSCs.
To quantify the proliferation of MSCs inside each
of the three scaffolds, CFSE-labeled MSCs were incu-
bated with scaffolds then cultured for 4 days. The
proportions of MSCs that have proliferated at day 5,
i.e., have a reduced expression of CFSE following
cell division compared to day 0 (Fig. 5D, left panel)
were quantified. The data demonstrated that the
numbers of proliferated MSCs inside Orthoss1 colla-
gen and Vitoss1 were comparable, however, signifi-
cantly greater compared to Orthoss1 (4.3 and 6.8-fold,
respectively, p¼ 0.047 and p¼0.004, respectively)
(Fig. 5D, right panel). Altogether, these data have
confirmed that the presence of collagen as a compo-
nent of bone scaffolds provided a better support for the
proliferation of MSCs.
DISCUSSION
The choice of scaffolds for the treatment of bone defects,
as biomechanical fillers or as carriers for MSCs, is
critical.27 As a prerequisite for bone tissue regenera-
tion, MSCs need to attach and proliferate on scaffolds
in order to subsequently differentiate and integrate
into the surrounding tissues. Here, we used as a model,
two scaffolds of the same basic composition (bovine
hydroxyapatite) to explore the effect of collagen incorpo-
ration on scaffold colonization by BM MSCs. Using
unprocessed BM aspirates, our data showed that the
addition of collagen to Orthoss1 collagen improved the
attachment, survival and proliferation of BM MSCs
compared to Orthoss1. A synthetic scaffold, Vitoss1,
was included as an additional collagen-containing scaf-
fold and showed similar results to Orthoss1 collagen.
To best of our knowledge, this study is the first to
quantitatively assess the attachment, survival and
proliferation of rare human non-cultured (unprocessed)
BM MSCs on these scaffolds.
The numbers of MSCs in BM aspirates are well
known to be low and variable because of sampling and
donor related factors particularly aging, which nega-
tively affects the number of BM MSCs.28,29 Our results
revealed a large variation in the numbers of MSCs
attached to scaffolds, independent on the scaffold type,
which in turn was related to the differences of the
initial quantity of MSCs in BM aspirates. The increase
in donor age was associated with the lower numbers of
aspirated and hence attached MSCs.
We have confirmed the morphology of BM MSCs
growing on Orthoss1 as flat and interconnected cells
bridging the pores of scaffold.19 However, cell attach-
ment was not clear on Orthoss1 collagen and Vitoss1.
For quantification of MSCs following their enzymatic
release from cultured scaffolds, we therefore developed
a flow-cytometry based method. In contrast to other
studies, in which MSC growth inside scaffolds was
tested using confocal/electron microscopy or via mea-
surement of total cellular DNA,19,30,31 the use of
flow-cytometry in our study has enabled us to quanti-
tatively assess scaffold colonization by MSCs as well
as by other BM cells. In one previous study, a flow-
cytometry assay was used to assess the viability of
culture-expanded MSCs seeded on 3D construct made
of a composite of hydroxyapatite and b-TCP, but the
assay was not quantitative.32
Our data shows that the number of BM MSCs
released from Orthoss1 collagen and Vitoss1 after
2-week in vitro culture was higher than Orthoss1,
clearly indicating that collagen-containing scaffolds
provided a more favourable environment for MSC
attachment and proliferation. Interestingly, the attach-
ment and proliferation of MSCs from BM aspirates into
Orthoss1 collagen and Vitoss1 were similar despite the
difference in their mineral composition. Complementary
to our results, Orthoss1 collagen and Vitoss1 have
been shown to equally support the osteogenic differenti-
ation of MSCs.33 The osteogenic potential of MSCs
colonizing the scaffolds was not tested in this study but
we have shown previously that Orthoss1 supports
osteogenic differentiation of MSCs after 3-weeks in
culture.19 Additionally, it has been shown that Vitoss1
supports the in vitro and in vivo osteogenic differentia-
tion of MSCs.34
It has been previously demonstrated that collagen-
mediated induction of MSC survival is a result of its
interaction with membrane-bound integrins on MSC
surface.35 Our study demonstrates that the incorpo-
ration of collagen into a natural bovine bone scaffold
supports the survival and proliferation of both culture-
expanded and non-expanded MSCs. Consistently, the
addition of collagen to nanocellulose- or chitosan-
made scaffolds has been shown to promote the
attachment of culture-expanded MSCs into these
scaffolds.36,37 Uniquely, we have evaluated the coloni-
zation of scaffolds by other BM cells, and not only
MSCs. Our results demonstrated that relative percen-
tages of BM MSCs inside Orthoss1 were higher
compared to collagen-containing scaffolds because the
latter scaffolds were more supportive for the attach-
ment and survival of other BM cells (myelomonocytic
or lymphocytic cells) in addition to MSCs. In agree-
ment, a collagen-containing scaffold has been shown to
provide an attachment to MSC as well as neutrophils
in an animal model of dental bone loss.38 Importantly,
regardless of scaffold type, we detected positive corre-
lations between the quantities of BM MSCs and
myelomonocytic or lymphocytic cells released from
scaffolds. These findings support the possibility that
BM-derived hematopoietic cells could have an addi-
tional positive effect on MSC growth on different bone
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scaffolds. Immune cells have been shown to enhance
the proliferation of animal BM MSCs.39,40 The inclu-
sion of other BM cells such as endothelial cells could
also support MSC proliferation.41 Therefore, our study
provides the platform for future investigation of the
effect of other BM cells on MSC survival, proliferation
and functions when loaded on osteoconductive scaf-
folds.
CONCLUSION AND FUTURE PERSPECTIVE
The preparation of culture-expanded MSCs for clinical
use is expensive and requires a complicated process of
regulation to ensure the clinical safety.42 Furthermore,
culture-expanded MSCs are seeded into scaffolds at
very high densities, which do not represent their
physiological densities in human bone23 or BM aspi-
rates.28,43,44 Our investigation reflects real clinical
procedure and shows that non-cultured MSCs from
unprocessed BM aspirates, despite their known low
frequency as well as donor and aspiration related
variation,28,43,45,46 can attach and proliferate on bone
scaffolds. Importantly, our data revealed that
the attachment, survival and proliferation of MSCs
were superior on collagen-containing scaffolds, a find-
ing which supports their broader use for orthopaedic
clinical applications.
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